Kura Oncology (KURA) Earns “Buy” Rating from Cann
“Kura Oncology had three positive presentations for its lead compound, Tipifarnib, at the 2017 American Society of Hematology meeting, from December 9-11. These included preliminary phase II analysis in CMML and PTCL, and a biomarker study. We found these studies very encouraging for Tipifarnib’s use in hematologic cancers. Our outlook for 2020-22 remains basically unchanged, and we estimate that Tipifarnib could result in sales as early as 2019. We currently estimate Tipifarnib could result in 2022 product sales of $1.1 billion. The data presented at 2017 ASH are very supportive of our outlook.”,” Cann’s analyst commented.
KURA has been the subject of several other research reports. Cowen started coverage on shares of Kura Oncology in a research note on Thursday, September 7th. They issued an outperform rating for the company. Zacks Investment Research raised shares of Kura Oncology from a hold rating to a buy rating and set a $7.75 target price for the company in a research note on Saturday, September 9th. Citigroup upped their target price on shares of Kura Oncology from $15.00 to $19.00 and gave the company a buy rating in a research note on Thursday, November 9th. ValuEngine downgraded shares of Kura Oncology from a hold rating to a sell rating in a research note on Friday, September 1st. Finally, Oppenheimer set a $18.00 target price on shares of Kura Oncology and gave the company a buy rating in a research note on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $17.90.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.01). equities research analysts forecast that Kura Oncology will post -1.5 earnings per share for the current fiscal year.
Large investors have recently modified their holdings of the business. State of Wisconsin Investment Board bought a new stake in Kura Oncology in the second quarter valued at approximately $102,000. Rhumbline Advisers acquired a new position in shares of Kura Oncology in the second quarter valued at approximately $131,000. New York State Common Retirement Fund acquired a new position in shares of Kura Oncology in the second quarter valued at approximately $142,000. OxFORD Asset Management LLP acquired a new position in shares of Kura Oncology in the second quarter valued at approximately $217,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Kura Oncology in the second quarter valued at approximately $226,000. 64.26% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Kura Oncology (KURA) Earns “Buy” Rating from Cann” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/14/kura-oncology-kura-earns-buy-rating-from-cann.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related stocks with our FREE daily email newsletter.